ETOPOSIDE
ETOPOSIDE
Indications:
Composition:
Generic: 50 mg
Solution, Intravenous:
[contains alcohol, usp, polyethylene glycol 300, polysorbate 80]
Generic: 100 mg/5 mL (5 mL); 500 mg/25 mL (25 mL); 1 g/50 mL (50 mL)
BEP regimen: 100 mg/m2 on days 1 to 4 every 3 weeks (in combination with bleomycin and
cisplatin) for at least 2 treatment cycles after a normal hCG level
Route:
Action:
Chemotherapy drugs that affect cells only when they are dividing are called cell-cycle
specific. Chemotherapy drugs that affect cells when they are at rest are called cell-cycle
non-specific. The scheduling of chemotherapy is set based on the type of cells, rate at
which they divide, and the time at which a given drug is likely to be effective. This is
why chemotherapy is typically given in cycles.
Distribution
Poor penetration across the blood-brain barrier; CSF concentrations <5% of plasma
concentrations.
Excretion
Children: IV: Urine (~55% as unchanged drug) in 24 hours
Adults: IV: Urine (56%; 45% as unchanged drug) within 120 hours; feces (44%) within 120
hours
Half-Life Elimination
Terminal: IV: Normal renal/hepatic function: Children: 6 to 8 hours: Adults: 4 to 11 hours
Side Effects:
The following side effects are common (occurring in greater than 30%) for patients taking
etoposide:
Low white blood cell count. (This can increase risk for infection).
Low platelet count (This can increase risk of bleeding).
Nadir: Meaning low point, nadir is the point in time between chemotherapy cycles in which
there is low blood counts.
Onset: 5-7 days
Nadir: 7-14 days
Recovery: 21-28 days
Hair loss
Menopause (chemotherapy induced)
Loss of fertility.
Nausea and vomiting (especially at high-doses)
Low blood pressure (if the drug is infused too fast)
These side effects are less common, meaning they occur in 10-29 percent of patients
receiving etoposide:
Delayed effects:
Precautions: Avoid
Health education: